Swedish Orphan Biovitrum AB (publ) is committed to upholding a strong set of values and corporate philosophy. The company prioritizes patient well-being and aims to make a positive impact on the lives of individuals affected by rare diseases. Swedish Orphan Biovitrum AB (publ) embraces an open and collaborative approach, fostering innovation and learning within the healthcare industry. With a focus on delivering high-quality therapies, the company strives to be a trusted partner for patients, healthcare providers, and society as a whole. Swedish Orphan Biovitrum AB (publ) consistently demonstrates its dedication to integrity, excellence, and sustainable practices.

Swedish Orphan Biovitrum AB (publ) primarily operates in various countries and regions worldwide. The company has a global presence, with a significant focus on Europe. It has established a strong presence in Nordic countries such as Sweden, Norway, Denmark, and Finland. Additionally, Swedish Orphan Biovitrum AB (publ) has expanded its operations to other European countries, including the United Kingdom, Germany, France, Italy, Spain, and Switzerland. It also has a growing presence in North America, particularly in the United States and Canada. Moreover, the company is actively exploring opportunities in emerging markets to further expand its geographical footprint.

Swedish Orphan Biovitrum AB has accomplished several significant milestones. Notably, the company successfully launched Elocta, a treatment for hemophilia, in multiple countries. It gained regulatory approvals for Alprolix, a therapy for hemophilia B, and Orfadin, a medication for the treatment of hereditary tyrosinemia type 1. Swedish Orphan Biovitrum AB (publ) also established strategic partnerships, including collaborations with Bioverativ, Biogen, and Novimmune. Moreover, the company expanded its product pipeline through acquisitions, such as Dova Pharmaceuticals and Emalex Biosciences. These achievements solidify Swedish Orphan Biovitrum AB's position as a leader in providing innovative treatments for rare diseases.

Swedish Orphan Biovitrum AB (publ) is a multinational pharmaceutical company focused on rare diseases and specialty care. Established in 2001, it has a rich history of developing innovative therapies to address unmet medical needs. The company operates across several therapeutic areas, including hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) collaborates with partners worldwide to advance their extensive product portfolio, leveraging their expertise to improve patients' lives. With a strong commitment to research and development, the company continues to make significant contributions to the field of healthcare. Swedish Orphan Biovitrum AB (publ) is dedicated to driving advancements in rare diseases and expanding access to life-changing treatments.

The main competitors of Swedish Orphan Biovitrum AB (publ) in the market include companies such as Novartis AG, Roche Holding AG, Biogen Inc., and Takeda Pharmaceutical Company Limited. These pharmaceutical companies operate in a similar market segment and represent strong competition for Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) is primarily active in the pharmaceutical industry.

The business model of Swedish Orphan Biovitrum AB (publ) focuses on developing and commercializing innovative treatments for rare diseases. The company specializes in providing therapies that address unmet medical needs, primarily within the areas of hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) engages in extensive research and development efforts to create effective and safe drugs for patients, collaborating with various partners in the healthcare industry. By prioritizing rare diseases and leveraging its expertise, Swedish Orphan Biovitrum AB (publ) aims to improve the lives of patients worldwide through its specialized treatments.

Swedish Orphan Biovitrum AB (publ)의 P/E 비율은 30.44입니다.

Swedish Orphan Biovitrum AB (publ)의 P/S 비율은 3.95입니다.

Swedish Orphan Biovitrum AB (publ)에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Swedish Orphan Biovitrum AB (publ) 매출은 25.49 조. SEK입니다.

예상되는 Swedish Orphan Biovitrum AB (publ) 이익은 3.31 조. SEK입니다.

Swedish Orphan Biovitrum AB is a biopharmaceutical company specializing in rare diseases and specialty medicines. It is divided into three main business areas: coagulation disorders, immunology, and genetics. The company develops, manufactures, markets, and distributes medications for these rare diseases. The coagulation disorders division focuses on products for the treatment of hemophilia, thrombosis prevention, and bleeding. The immunology division focuses on products for the treatment of rare diseases such as hereditary angioedema and primary immune thrombocytopenia. The genetics division focuses on products for the treatment of rare genetic diseases such as Gaucher's disease, Fabry disease, and Pompe disease. The company distributes its products globally and works closely with patient organizations and healthcare providers to ensure access to medication and information for patients with rare diseases. The company also invests heavily in research and development for new therapies and diagnostic procedures for rare diseases. The business model of Swedish Orphan Biovitrum is based on the production and marketing of specialty medicines for the treatment of rare diseases. It focuses on niche markets where it has strong expertise and collaborates with patient organizations and healthcare providers to meet patient needs. The company achieves high value creation and builds a differentiated competitive advantage by focusing on rare diseases.

Swedish Orphan Biovitrum AB (publ)은(는) 연간 번의 배당을 통해 0 SEK의 배당금을 지급합니다.

Swedish Orphan Biovitrum AB (publ)의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Swedish Orphan Biovitrum AB (publ)의 ISIN은 SE0000872095입니다.

Swedish Orphan Biovitrum AB (publ)의 WKN은 A0LA5K입니다.

Swedish Orphan Biovitrum AB (publ)의 티커는 SOBI.ST입니다.

지난 12개월 동안 Swedish Orphan Biovitrum AB (publ)은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Swedish Orphan Biovitrum AB (publ)은(는) 0 SEK의 배당금을 지급할 것으로 예상됩니다.

Swedish Orphan Biovitrum AB (publ)의 현재 배당 수익률은 입니다.

Swedish Orphan Biovitrum AB (publ)은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Swedish Orphan Biovitrum AB (publ)은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 SEK의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Swedish Orphan Biovitrum AB (publ)은 '건강' 섹터에 속합니다.

Swedish Orphan Biovitrum AB (publ)의 마지막 배당금을 0 SEK만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Swedish Orphan Biovitrum AB (publ)는 0 SEK를 배당금으로 지급했습니다.

Swedish Orphan Biovitrum AB (publ)의 배당금은 SEK에 지급됩니다.